Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting
Status: | Completed |
---|---|
Conditions: | Neurology, Psychiatric, ADHD |
Therapuetic Areas: | Neurology, Psychiatry / Psychology, Other |
Healthy: | No |
Age Range: | 6 - 12 |
Updated: | 10/14/2017 |
Start Date: | December 2010 |
End Date: | February 2012 |
A Randomized, Double-Blind Study of the Time Course of Response to Biphentin Methylphenidate Hydrochloride ER Capsules Compared to Placebo in Children 6 to 12 Years With Attention Deficit Hyperactivity Disorder in Analog Classroom Setting
The time course of response following one dose of a new methylphenidate hydrochloride
extended release capsule is studied in children 6-12 years in a simulated laboratory
classroom setting. Biphentin methylphenidate hydrochloride extended release capsule has been
formulated for daily dosing to provide treatment of a child with ADHD for the substantial
day.
extended release capsule is studied in children 6-12 years in a simulated laboratory
classroom setting. Biphentin methylphenidate hydrochloride extended release capsule has been
formulated for daily dosing to provide treatment of a child with ADHD for the substantial
day.
Biphentin methylphenidate hydrochloride extended release capsules is provided in multiple
strengths of 10, 15, 20, 30, 40, 50, and 60 mg to be administered once daily. Once daily
dosing is intended to provide treatment for the substantial day.
For current analog classroom study each eligible subject will be optimized at 15, 20, 30, or
40 mg in a timeframe of five weekly periods. In the sixth week each subject will be
randomized double-blind to receive either active comparator at the optimized dose or placebo
comparator treatment. The first classroom session will be held at the end of the week, when
efficacy measurements including SKAMP and PERMP tests will be administered. At the beginning
of the following week, the subjects will be crossed-over to the corresponding active
comparator or placebo comparator treatment. The second classroom session will be held at the
end of the second double-blind week, when the same efficacy measurements will be
administered.
Various safety and tolerability, and quality of life assessments will be conducted.
strengths of 10, 15, 20, 30, 40, 50, and 60 mg to be administered once daily. Once daily
dosing is intended to provide treatment for the substantial day.
For current analog classroom study each eligible subject will be optimized at 15, 20, 30, or
40 mg in a timeframe of five weekly periods. In the sixth week each subject will be
randomized double-blind to receive either active comparator at the optimized dose or placebo
comparator treatment. The first classroom session will be held at the end of the week, when
efficacy measurements including SKAMP and PERMP tests will be administered. At the beginning
of the following week, the subjects will be crossed-over to the corresponding active
comparator or placebo comparator treatment. The second classroom session will be held at the
end of the second double-blind week, when the same efficacy measurements will be
administered.
Various safety and tolerability, and quality of life assessments will be conducted.
Inclusion Criteria:
1. Males and females ages 6 to 12.
2. ADHD diagnosis with ADHD-RS-IV scores ≥ 90th percentile.
3. In need of treatment for ADHD and able to have 2-day washout from previous medication.
4. Females of child-bearing potential not pregnant and practice birth control.
5. Subject and parent/guardian willing to comply with protocol.
6. Signed consent and assent.
Exclusion Criteria:
1. IQ less than 80 WASI.
2. Current primary psychiatric diagnosis of: severe anxiety disorder, conduct disorder,
psychotic disorders, pervasive developmental disorder, eating disorder,
obsessive-compulsive disorder, major depressive disorder, bipolar disorder, substance
use disorder, chronic tic disorder, personal or family history of Tourette's Syndrome.
3. Chronic medical illnesses: seizure, hypertension, thyroid disease, cardiac, family
history of sudden death, glaucoma.
4. Use of psychotropic CNS meds having effect exceeding 14 days from screening.
5. Planned use of prohibited drugs.
6. Is pregnant or breast-feeding.
7. Significant ECG or laboratory abnormalities.
8. Experimental drug or medical device within 30 days prior to screening.
9. Hypersensitivity to methylphenidate.
10. Inability or unwillingness to comply with protocol.
11. Well controlled on current ADHD treatment.
12. Inability to take oral capsules.
We found this trial at
1
site
Click here to add this to my saved trials